Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Aligos Therapeutics, Inc. (ALGS) had Income from Continuous Operations of $43.09M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.31M |
|
$-18.41M |
|
-- |
|
$0.31M |
|
$19.55M |
|
$-19.24M |
|
$62.37M |
|
$43.13M |
|
$43.13M |
|
$43.09M |
|
|
Income from Continuous Operations |
$43.09M |
$43.09M |
|
$43.09M |
|
$-19.24M |
|
$-18.87M |
|
8.41M |
|
8.71M |
|
$-2.11 |
|
$-2.11 |
|
| Balance Sheet Financials | |
$143.21M |
|
$2.21M |
|
$7.49M |
|
$150.70M |
|
$18.95M |
|
$0.12M |
|
$15.31M |
|
$34.25M |
|
$116.44M |
|
$116.44M |
|
$116.44M |
|
6.12M |
|
| Cash Flow Statement Financials | |
$-20.91M |
|
$-44.07M |
|
$101.74M |
|
$37.11M |
|
$73.87M |
|
$36.77M |
|
$0.96M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.56 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
100.00% |
|
-6187.46% |
|
-6187.46% |
|
-- |
|
13868.49% |
|
-5918.33% |
|
$-20.95M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
37.00% |
|
37.00% |
|
28.59% |
|
36.96% |
|
$19.04 |
|
$-2.41 |
|
$-2.40 |
|